Amisha Wallia1, Mark E Molitch1. 1. Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
IMPORTANCE: The incidence and prevalence of type 2 diabetes mellitus are increasing. OBJECTIVE: To review currently available insulin therapy, as well as evidence on the use, application, initiation, and intensification of insulin in the outpatient setting. EVIDENCE REVIEW: Data sources included PubMed for trials and investigations in type 2 diabetes examining insulin use from January 1998 to April 2014. FINDINGS: The hemoglobin A1c target for most patients with type 2 diabetes is 7% but needs to be modified when there is increased risk of hypoglycemia, reduced life expectancy, extensive comorbidities, or reduced resources. Insulin therapy may be considered early or late in the disease course; adverse effects include weight gain and hypoglycemia. Basal insulin can be added to oral hypoglycemic agents (generally stopping sulfonylureas) initially, and later, prandial insulin can be added in a stepwise fashion. Insulin treatment must be individualized, and there are a number of challenges to insulin initiation and intensification. CONCLUSIONS AND RELEVANCE: Insulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes. Barriers such as adherence, patient preferences, clinician preferences, and resource allocation must be addressed.
IMPORTANCE: The incidence and prevalence of type 2 diabetes mellitus are increasing. OBJECTIVE: To review currently available insulin therapy, as well as evidence on the use, application, initiation, and intensification of insulin in the outpatient setting. EVIDENCE REVIEW: Data sources included PubMed for trials and investigations in type 2 diabetes examining insulin use from January 1998 to April 2014. FINDINGS: The hemoglobin A1c target for most patients with type 2 diabetes is 7% but needs to be modified when there is increased risk of hypoglycemia, reduced life expectancy, extensive comorbidities, or reduced resources. Insulin therapy may be considered early or late in the disease course; adverse effects include weight gain and hypoglycemia. Basal insulin can be added to oral hypoglycemic agents (generally stopping sulfonylureas) initially, and later, prandial insulin can be added in a stepwise fashion. Insulin treatment must be individualized, and there are a number of challenges to insulin initiation and intensification. CONCLUSIONS AND RELEVANCE: Insulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes. Barriers such as adherence, patient preferences, clinician preferences, and resource allocation must be addressed.
Authors: Reimar W Thomsen; Lisbeth M Baggesen; Mette Søgaard; Lars Pedersen; Helene Nørrelund; Esben S Buhl; Christiane L Haase; Søren P Johnsen Journal: Diabetologia Date: 2015-08-16 Impact factor: 10.122
Authors: Kyoungmin Park; Qian Li; Net Daş Evcimen; Christian Rask-Madsen; Yasutaka Maeda; Ernesto Maddaloni; Hisashi Yokomizo; Takanori Shinjo; Ronald St-Louis; Jialin Fu; Daniel Gordin; Mogher Khamaisi; David Pober; Hillary Keenan; George L King Journal: Arterioscler Thromb Vasc Biol Date: 2017-11-21 Impact factor: 8.311
Authors: Jason M Cox; Hong D Chu; Mariappan V Chelliah; John S Debenham; Keith Eagen; Ping Lan; Matthew Lombardo; Clare London; Michael A Plotkin; Unmesh Shah; Zhongxiang Sun; Henry M Vaccaro; Srikanth Venkatraman; Takao Suzuki; Nengxue Wang; Eric R Ashley; Alejandro Crespo; Maria Madeira; Dennis H Leung; Candice Alleyne; Aimie M Ogawa; Sarah Souza; Brande Thomas-Fowlkes; Jerry Di Salvo; Adam Weinglass; Melissa Kirkland; Michele Pachanski; Mary Ann Powles; Effie Tozzo; Taro E Akiyama; Feroze Ujjainwalla; James R Tata; Christopher J Sinz Journal: ACS Med Chem Lett Date: 2016-11-17 Impact factor: 4.345
Authors: Derek LeRoith; Geert Jan Biessels; Susan S Braithwaite; Felipe F Casanueva; Boris Draznin; Jeffrey B Halter; Irl B Hirsch; Marie E McDonnell; Mark E Molitch; M Hassan Murad; Alan J Sinclair Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: Matthew J O'Brien; Susan L Karam; Amisha Wallia; Raymond H Kang; Andrew J Cooper; Nicola Lancki; Margaret R Moran; David T Liss; Theodore A Prospect; Ronald T Ackermann Journal: JAMA Netw Open Date: 2018-12-07
Authors: S M Lenherr; J Q Clemens; B H Braffett; R L Dunn; P A Cleary; C Kim; W H Herman; J M Hotaling; A M Jacobson; J S Brown; H Wessells; A V Sarma Journal: Diabet Med Date: 2016-04-24 Impact factor: 4.359